Home
April 2008 May 2008 June 2008
Su Mo Tu We Th Fr Sa
Week 18 1 2 3
Week 19 4 5 6 7 8 9 10
Week 20 11 12 13 14 15 16 17
Week 21 18 19 20 21 22 23 24
Week 22 25 26 27 28 29 30 31

Hypogonadism in Men Receiving Methadone and Buprenorphine Maintenance Treatment - Abstract Show Comments PDF Print E-mail
  
Wednesday, 28 November 2007

The Byrne Surgery, Redfern, NSW, Australia

The aim of this study was to determine the prevalence and investigate the aetiology of hypogonadism in men on methadone or buprenorphine maintenance treatment (MMT, BMT). 103 men (mean age 37.6 +/- 7.9) on MMT (n = 84) or BMT (n = 19) were evaluated using hormone assays, body mass index (BMI), serological, biochemical, demographic and substance use measures. Overall 54% of men (methadone 65%; buprenorphine 28%) had total testosterone (TT) <12.0 nm; 34% (methadone 39%; buprenorphine 11%) had TT <8.0 nm. Both methadone- and buprenorphine-treated men had lower free testosterone, luteinising hormone and estradiol than age-matched reference groups. Methadone-treated men had lower TT than buprenorphine-treated men and reference groups. Prolactin did not differ between methadone, buprenorphine groups, and reference groups. Primary testicular failure was an uncommon cause of hypogonadism. Yearly percentage fall in TT by age across the patient group was 2.3%, more than twice that expected normally. There were no associations between TT and opioid dose, cannabis, alcohol and tobacco consumption, or chronic hepatitis C viraemia. On multiple regression higher TT was associated with higher alanine aminotransferase and lower TT with higher BMI. Men on MMT have high prevalence of hypogonadotrophic hypogonadism. The extent of hormonal changes associated with buprenorphine needs to be explored further in larger studies. Men receiving long term opioid replacement treatment, especially methadone treatment, should be screened for hypogonadism. Wide interindividual differences in methadone metabolism and tolerance may in a cross-sectional study obscure a methadone dose relationship to testosterone in individuals. Future studies of hypogonadism in opioid-treated men should examine the potential benefits of dose reduction, choice of opioid medication, weight loss, and androgen replacement.

Written by
Hallinan R, Byrne A, Agho K, McMahon CG, Tynan P, Attia J.

Reference
Int J Androl. 2007 Oct 30; [Epub ahead of print]
doi:10.1111/j.1365-2605.2007.00824.x

PubMed Abstract
PMID:17971165

UroToday.com Androgen Deficiency Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 
< Prev   Next >